The μ-opioid receptor in cancer progression: Is there a direct effect?

Anesthesiology

Volumn 116, Issue 4, 2012, Pages 940-945

  Lennon, Frances E ^a   Moss, Jonathan ^a   Singleton, Patrick A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; BETA ENDORPHIN; BEVACIZUMAB; DELTA OPIATE RECEPTOR; DIAMORPHINE; ENDORPHIN; FENTANYL; FLUOROURACIL; INTERLEUKIN 2; KAPPA OPIATE RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; METHADONE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE B; PROTEIN KINASE P60; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TEMSIROLIMUS; THIOCTIC ACID; VASCULOTROPIN;

ADDICTION; ADJUVANT THERAPY; ALLELE; ANALGESIA; ANGIOGENESIS; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COLON CANCER; CONSTIPATION; CYTOTOXICITY; DISEASE FREE SURVIVAL; DISEASE MODEL; ENDOCYTOSIS; GENERAL ANESTHESIA; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NATURAL KILLER CELL; NONHUMAN; NOTE; PANCREAS CANCER; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; DISEASE PROGRESSION; HUMANS; NARCOTIC ANTAGONISTS; NEOPLASM INVASIVENESS; NEOPLASMS; RECEPTORS, OPIOID, MU;

EID: 84859106120     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31824b9512     Document Type: Note

References (39)

1. Bovill JG: Surgery for cancer: Does anesthesia matter? Anesth Analg 2010; 110:1524-6
2. Schlagenhauff B, Ellwanger U, Breuninger H, Stroebel W, Rassner G, Garbe C: Prognostic impact of the type of anaesthesia used during the excision of primary cutaneous melanoma. Melanoma Res 2000; 10:165-9 (Pubitemid 30256879)
3. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI: Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? ANESTHESIOLOGY 2006; 105:660-4 (Pubitemid 44477309)
4. Christopherson R, James KE, Tableman M, Marshall P, Johnson FE: Long-term survival after colon cancer surgery: A variation associated with choice of anesthesia. Anesth Analg 2008; 107:325-32
5. Gottschalk A, Ford JG, Regelin CC, You J, Mascha EJ, Sessler DI, Durieux ME, Nemergut EC: Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. ANESTHESIOLOGY 2010; 113:27-34
6. Myles PS, Peyton P, Silbert B, Hunt J, Rigg JR, Sessler DI: Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival. randomised trial. BMJ 2011; 342:d1491
7. Tavare AN, Perry NJ, Benzonana LL, Takata M, Ma D: Cancer recurrence after surgery: Direct and indirect effects of anesthetic agents. Int J Cancer 2012; 130:1237-50
8. Wuethrich PY, Hsu Schmitz SF, Kessler TM, Thalmann GN, Studer UE, Stueber F, Burkhard FC: Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome: A retrospective study. ANESTHESIOLOGY 2010; 113:570-6
9. Welden B, Gates G, Mallari R, Garrett N: Effects of anesthetics and analgesics on natural killer cell activity. AANA J 2009; 77:287-92
10. Snyder GL, Greenberg S: Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105:106-15
11. Gach K, Wyrȩbska A, Fichna J, Janecka A: The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol 2011; 384:221-30
12. Yeager MP, Rosenkranz KM: Cancer recurrence after surgery: A role for regional anesthesia? Reg Anesth Pain Med 2010; 35:483-4
13. Singleton PA, Moss J: Effect of perioperative opioids on cancer recurrence: A hypothesis. Future Oncol 2010; 6:1237-42
14. Afsharimani B, Cabot P, Parat MO: Morphine and tumor growth and metastasis. Cancer Metastasis Rev 2011; 30:225-38
15. Al-Hasani R, Bruchas MR: Molecular mechanisms of opioid receptor-dependent signaling and behavior. ANESTHESIOLOGY 2011; 115:1363-81
16. Kasai S, Ikeda K: Pharmacogenomics of the human μ-opioid receptor. Pharmacogenomics 2011; 12:1305-20
17. Moss J, Rosow CE: Development of peripheral opioid antagonists'new insights into opioid effects. Mayo Clin Proc 2008; 83:1116-30
18. Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D, Hebbel RP: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62:4491-8 (Pubitemid 34827313)
19. Wolf NB, Küchler S, Radowski MR, Blaschke T, Kramer KD, Weindl G, Kleuser B, Haag R, Schäfer-Korting M: Influences of opioids and nanoparticles on in vitro wound healing models. Eur J Pharm Biopharm 2009; 73:34-42
20. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J: Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation. Microvasc Res 2006; 72:3-11 (Pubitemid 44118390)
21. Leo S, Nuydens R, Meert TF: Opioid-induced proliferation of vascular endothelial cells. J Pain Res 2009; 2:59-66
22. Zhang L, Zhao H, Qiu Y, Loh HH, Law PY: Src phosphorylation of micro-receptor is responsible for the receptor switching from an inhibitory to a stimulatory signal. J Biol Chem 2009; 284:1990-2000
23. Singleton PA, Garcia JG, Moss J: Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis. Mol Cancer Ther 2008; 7:1669-79
24. Singleton PA, Mambetsariev N, Lennon FE, Mathew B, Siegler JH, Moreno-Vinasco L, Salgia R, Moss J, Garcia JG: Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors. J Angiogenes Res 2010; 2:5
25. Boehncke S, Hardt K, Schadendorf D, Henschler R, Boehncke WH, Duthey B: Endogenous μ-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol 2011; 20:24-8
26. Dai X, Cui SG, Wang T, Liu Q, Song HJ, Wang R: Endogenous opioid peptides, endomorphin-1 and -2 and deltorphin I, stimulate angiogenesis in the CAM assay. Eur J Pharmacol 2008; 579:269-75
27. Mathew B, Lennon FE, Siegler J, Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere PJ, Chen CT, Garcia JG, Salgia R, Moss J, Singleton PA: The novel role of the mu opioid receptor in lung cancer progression: A laboratory investigation. Anesth Analg 2011; 112:558-67
28. Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton P: Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. ANESTHESIOLOGY 2012; 116:857-67
29. McLaughlin PJ, Stucki J, Zagon IS: Inhibition of cancer progression by upregulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis using imquimod or low dose naltrexone (abstract 679). In Proceedings of the 101st Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC, April 17-21, 2010. Philadelphia, AACR, 2010
30. Berkson BM, Rubin DM, Berkson AJ: Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: A report of 3 new cases. Integr Cancer Ther 2009; 8:416-22
31. Koodie L, Ramakrishnan S, Roy S: Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. Am J Pathol 2010; 177:984-97
32. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Català E, Bryce DA, Coyne PJ, Pool GE, Implantable Drug Delivery Systems Study Group: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20:4040-9
33. Chen YL, Law PY, Loh HH: The other side of the opioid story: Modulation of cell growth and survival signaling. Curr Med Chem 2008; 15:772-8 (Pubitemid 351516793)
34. Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C: Human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci USA 2011; 108:9268-73
35. Bortsov AV Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA: μ-opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. ANESTHESIOLOGY 2012; 116:896-902
36. Pantel K, Alix-Panabières C: Circulating tumour cells in cancer patients: Challenges and perspectives. Trends Mol Med 2010; 16:398-406
37. Le Guelte A, Dwyer J, Gavard J: Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Biol Cell 2011; 103:593-605
38. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG: Attenuation of vascular permeability by methylnaltrexone: Role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 2007; 37:222-31 (Pubitemid 47255005)
39. Yuan CS, Foss JF, O'Connor M, Osinski J, Karrison T, Moss J, Roizen MF: Methylnaltrexone for reversal of constipation due to chronic methadone use: A randomized controlled trial. JAMA 2000; 283:367-72 (Pubitemid 30051755)